Long-term results of treatment of lung cancer patients with paraneoplastic rheumatic syndrome

Summary. Research is devoted to study and comparative analysis of total cumulative survival of lung cancer patients without paraneoplastic rheumatic syndrome (PNRS) and with PNRS depending on stage, localization of tumor, histological form, tumour grade, methods of treatment. It was established that total cumulative survival in lung cancer patients with PNRS lower (p<0.01) than of similar patients without PNRS (five-year survival 10.89±4.14 and 17.64±2.15% respectively) at all terms of observation. It is proved that total cumulative survival of lung cancer patients with IIIB and IV stage, with central cancer, adenocarcinoma and small cell cancer in patients with symptoms PNRS lower (p<0.05) than that of similar patients without PNRS at all terms of observation. When comparing the long-term results of conservative antitumor treatment of lung cancer patients according to PNRS shows that in lung cancer patients without PNRS total cumulative survival was significantly higher than of similar patients with PNRS. This also applies to lung cancer patients who did not receive any special treatment. 5-year overall survival (27.34±10.13%) is the best in lung cancer patients with PNRS who were treated surgically, in contrast to patients receiving conservative treatment.